Talis Biomedical Corp Ordinary Shares TLIS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLIS is a good fit for your portfolio.
News
-
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Talis, TaskUs, and RTR on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Trading Information
- Previous Close Price
- $9.13
- Day Range
- $9.02–9.02
- 52-Week Range
- $4.41–9.38
- Bid/Ask
- $8.71 / $9.25
- Market Cap
- $16.43 Mil
- Volume/Avg
- 150 / 9,322
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 39.68
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 99
- Website
- https://talisbio.com
Valuation
Metric
|
TLIS
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.24 |
Price/Sales | 39.68 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
TLIS
|
---|---|
Quick Ratio | 8.75 |
Current Ratio | 8.86 |
Interest Coverage | — |
Quick Ratio
TLIS
Profitability
Metric
|
TLIS
|
---|---|
Return on Assets (Normalized) | −43.75% |
Return on Equity (Normalized) | −56.74% |
Return on Invested Capital (Normalized) | −46.35% |
Return on Assets
TLIS
Medical Devices Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ABT
| Abbott Laboratories | Nmcgvrz | Mbxqjs | $184.4 Bil | |
SYK
| Stryker Corp | Cqxzjsjbms | Kmsft | $125.0 Bil | |
MDT
| Medtronic PLC | Lzwbpjyjw | Qvpqqxs | $107.4 Bil | |
BSX
| Boston Scientific Corp | Vkynxwzyc | Ydvsh | $106.2 Bil | |
EW
| Edwards Lifesciences Corp | Zxyynzmlhw | Ydmwjbn | $50.8 Bil | |
DXCM
| DexCom Inc | Jldvsnddh | Jzkt | $49.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Scgtwmktp | Mrwzf | $24.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Xyfznkbfz | Sqzwn | $24.4 Bil | |
ALGN
| Align Technology Inc | Njqwcmhjl | Kdtxhz | $21.4 Bil | |
PODD
| Insulet Corp | Xvgjgnhm | Fvtkz | $11.9 Bil |